Glycoprotein News and Research

RSS

Study finds correlation between neutralizing antibody titer and reported vaccine efficacy

An observational study compares immune responses against three vaccines.

29 Sep 2021

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

New findings identify CASP4/11 as detrimental to inflammation and coagulopathy associated with SARS-CoV-2 infection.

28 Sep 2021

New study clears a pharmacologic hurdle in developing molecularly targeted therapies for AML

New research from Johns Hopkins Kimmel Cancer Center investigators shows why some drugs in clinical trials for treating a form of acute myeloid leukemia (AML) often fail and demonstrates a way to restore their effectiveness.

27 Sep 2021

How SARS-CoV-2 spike binds to multiple host receptors

Researchers from the Genos Glycoscience Research Laboratory in Croatia have recently investigated the sites that the S protein is capable of binding with.

23 Sep 2021

SARS-CoV-2 genome signature leads to replicative advantage in presence of Remdesivir

A new study indicates that low-level resistance of SARS-CoV-2 to remdesivir is not widespread and dissimilar to other RNA viruses revealing evolutionary predictability of this pandemic virus.

22 Sep 2021

Is the Pfizer-BioNTech COVID vaccine still effective after 6 months?

A team of researchers assessed the effectiveness of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine.

21 Sep 2021

This 3D modeling reveals how SARS-CoV-2 attacks

Now, researchers at the Garvan Institute of Medical Research, Darlinghurst in Australia, CSIRO Data61, and the School of Biotechnology and Biomolecular Sciences (UNSW) demonstrated the most comprehensive analysis of the three-dimensional structure of SARS-CoV-2, providing a new insight into how the virus infects cells and replicates.

16 Sep 2021

Prior symptomatic COVID-19 enhances mRNA vaccine response

A new paper describes the antibody responses in people who have already been infected with SARS-CoV-2 and are vaccinated as compared to the naïve.

14 Sep 2021

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

This study revealed that the CV3-13 antibody can mediate Fc effector functions against S protein-expressing cells.

13 Sep 2021

The strengths and weaknesses of the spike protein in SARS-CoV-2 variants

The S protein has the ability to appropriate various conformations that are dependent on the formation of the receptor-binding domain (RBD) of its protomers.

12 Sep 2021

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust and long-lived humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both young and aging mice.

8 Sep 2021

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Scientists from the National Institutes of Health, USA, have recently demonstrated the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based coronavirus disease 2019 (COVID-19) vaccines in hamsters.

6 Sep 2021

Study finds a restricted number of possible escape mutations for SARS-CoV-2 Delta variant

The emergence of escape mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is somewhat less likely for the Delta variant in comparison with the original or wild type virus, shows a recent study currently available on the bioRxiv* preprint server while it undergoes peer review.

5 Sep 2021

Do kidney transplant recipients need a third booster dose of mRNA COVID-19 vaccine?

A team of researchers in France have observed that the “standard” 2 dose regimen for mRNA COVID-19 vaccines could provide adequate protection to only a few KTRs. It has also been shown in multiple studies that a considerable population of vaccinated KTRs were easily infected with SARS-CoV-2.

1 Sep 2021

Attenuated virulence and protective immunity in SARS-CoV-2 with a mutation in the S1/S2 cleavage site

A new study published in mBio investigates the impact of the furin cleavage site on viral growth and pathogenesis.

31 Aug 2021

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.

30 Aug 2021

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Self-amplifying RNA (saRNA) is an advanced platform for nucleic acid vaccine development. The backbone is typically derived from an alphaviral genome and encodes a gene of interest (GOI) and a viral replicase that can amplify the genomic and subgenomic RNA.

30 Aug 2021

The influence of COVID-19 on platelet activation and aggregation

In a paper recently uploaded to the bioRxiv* preprint server, humanized ACE2 mice are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and platelets are subsequently isolated from the blood for quantitative proteomic analysis.

26 Aug 2021

SARS-CoV-2 alpha variant increased COVID-19 severity in Scotland's 3rd wave

A team of UK-based scientists has recently revealed that the alpha variant (B.1.1.7) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the third pandemic wave in Scotland and that the variant is associated with more severe coronavirus disease 2019 (COVID-19). The study is currently available on the medRxiv* preprint server.

25 Aug 2021

The emergence and spread of the SARS-CoV-2 Lambda (B.1.621) variant

A new study details the genomic characteristics and descent of a SARS-CoV-2 variant of interest.

23 Aug 2021